IsoTis S.A. (Irvine, CA, Lausanne, Switzerland)
CMDF Investment: $8,065,000 
Public (TSX : ISO;SWX:ISO)
Focus:Osteoporosis  Other  
Company Website

IsoTis OrthoBiologics was created in Q4 2003 through the merger of GenSci OrthoBiologics; a US-based orthobiology company; and IsoTis SA; a Swiss-Dutch biomedical company. The company operates out of its corporate headquarters in Lausanne; Switzerland; and its facilities in Bilthoven; The Netherlands and in Irvine; California; US. IsoTis OrthoBiologics has approximately 150 employees; a product portfolio with 6 orthobiology products on the market and 9 others in development; pro-forma product sales of US$ 23 million in 2002; an established North American independent distribution network of 400 sales representatives; and a rapidly expanding international presence. The field of orthobiologics combines advances in biotechnology; materials sciences and tissue biology to promote and enhance the body's natural ability to regenerate and repair musculoskeletal tissue. The company is a dedicated and global orthobiologics player focused on the market of orthopaedics and bone graft substitutes. IsoTis is developing a broad presence in both "natural" demineralized bone matrix (DBM) products and "synthetic" bone graft substitutes; carrier technologies and biologically-based growth factors. Orthobiologics is the fastest growing segment of the US$16 billion orthopedics market.